Kwangdong Pharmaceutical announced on July 24 that it has signed an exclusive domestic sales and distribution contract with Italy’s rare disease drug specialist Chiesi.As a result, Kwangdong Pharmaceutical now holds the exclusive domestic sales and distribution rights for three of Chiesi’s rare dise
The Korean biotech ecosystem appears to have reached maturity as a growing number of small and medium-sized companies hit the jackpot in addition to such large companies as SK Biopharm and Celltrion.South Korean Biotech venture companies posted about 5 trillion won in technology export in the second
Tium Bio announced on Jan. 10 that it signed a technology export agreement worth US$74 million (83 billion won) with Chiesi Farmaceutici, an Italian global pharmaceutical company, for NCE401, which is a major therapeutic drug candidate for lung disease.NCE401 is a candidate for a mechanism that inhi